Marex Group plc Announces Launch of Initial Public Offering
15 April 2024 - 3:19PM
Marex Group plc (“Marex”), the diversified global financial
services platform, today announces that it has launched the initial
public offering (the “IPO”) of its ordinary shares. A total of
15,384,615 ordinary shares are being offered, 25% of which are
being offered by Marex and 75% of which are being offered by
certain selling shareholders (the “Selling Shareholders”).
In connection with the offering, the Selling
Shareholders have granted the underwriters a 30-day option to
purchase up to an additional 2,307,692 ordinary shares to cover
over-allotments. The IPO price is currently estimated to be between
$18 and $21 per share. Marex’s ordinary shares are expected to
trade on the Nasdaq Global Select Market under the ticker symbol
“MRX”.
Barclays, Goldman Sachs & Co. LLC, Jefferies
and Keefe, Bruyette & Woods, a Stifel Company, are acting as
joint lead book-running managers and as representatives of the
underwriters for the proposed offering.
Citigroup, UBS Investment Bank, Piper Sandler
and HSBC are acting as bookrunners for the proposed offering.
Drexel Hamilton and Loop Capital Markets are acting as co-managers
for the proposed offering.
The proposed offering will be made only by means
of a prospectus. Copies of the preliminary prospectus relating to
the proposed offering may be obtained from:
- Barclays Capital Inc., c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, by telephone at 1-888-603-5847, or by email at
barclaysprospectus@broadridge.com;
- Goldman Sachs & Co. LLC,
Attention: Prospectus Department, 200 West Street, New York, New
York 10282, via telephone: 1-866-471-2526, or via email:
prospectus-ny@ny.email.gs.com;
- Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, New York, NY
10022, by phone at (877) 821-7388, or by email at
Prospectus_Department@Jefferies.com; or
- Keefe, Bruyette & Woods Inc.,
787 Seventh Avenue, Fourth Floor, New York, NY 10019, attention:
Equity Capital Markets, or by calling toll free at (800) 966-1559
or emailing USCapitalMarkets@kbw.com.
A registration statement relating to these
securities has been filed with the U.S. Securities and Exchange
Commission but has not yet become effective. These securities may
not be sold, nor may offers to buy these securities be accepted,
prior to the time the registration statement becomes effective.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any securities, and shall not
constitute an offer, solicitation or sale in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of that
jurisdiction.
Enquiries please contact:
Nicola Ratchford / Robert CoatesMarex +44 (0) 7786548889 / +44
(0) 7880486329| nratchford@marex.com / RCoates@marex.com
FTI Consulting US / UK+1 (919) 609-9423 / +44 (0) 7776 111 222 |
marex@fticonsulting.com
Marex (NASDAQ:MRX)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Marex (NASDAQ:MRX)
Historical Stock Chart
Von Jan 2024 bis Jan 2025